Antares Pharma Inc Revenue Growth Rates (ATRS), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Antares Pharma Inc   (NASDAQ: ATRS)
 

ATRS's Revenue Growth by Quarter and Year

Antares Pharma Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ATRS Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 41.56
FY 41.56

ATRSs Annual Revenue
Antares Pharma Inc 's Revenue in the fiscal year 2021 $ 183.98 millions
Antares Pharma Inc 's Revenue in the fiscal year 2020 $ 149.60 millions
Antares Pharma Inc 's Revenue in the fiscal year 2019 $ 123.86 millions
Antares Pharma Inc 's Revenue in the fiscal year 2018 $ 63.55 millions
Antares Pharma Inc 's Revenue in the fiscal year 2017 $ 54.52 millions




ATRS Revenue first quarter 2022 Y/Y Growth Comment
Antares Pharma Inc reported decrease in Revenue in the first quarter 2022 by -1.24% to $ 41.56 millions, from the same quarter in 2021.
The decrease in the first quarter 2022 Antares Pharma Inc 's Revenue compares unfavorably to the Company's average Revenue rise of 30.74%.

Looking into first quarter 2022 results within Medical Equipment & Supplies industry 149 other companies have achieved higher Revenue growth. While Antares Pharma Inc ' s Revenue decline of -1.24% ranks overall at the positon no. 3450 in the first quarter 2022.


ATRS Revenue ( Y/Y Growth %) 2022
 2021 2020 2019
4th Quarter December - 10.42 % 16.62 % 101.06 %
3rd Quarter September - 20.47 % 16.58 % 92 %
2nd Quarter June - 38.91 % 13.89 % 100.78 %
1st Quarter March -1.24 % 27.21 % 42.04 % 83.39 %
FY   - 22.99 % 20.76 % -

Financial Statements
Antares Pharma Inc 's first quarter 2022 Revenue $ 41.56 millions ATRS's Income Statement
Antares Pharma Inc 's first quarter 2021 Revenue $ 42.08 millions Quarterly ATRS's Income Statement


ATRS Revenue (Quarter on Quarter Growth %)

 2022
 2021 2020 2019
4th Quarter December - 1.12 % 10.33 % 10.29 %
3rd Quarter September - 7.14 % 23.53 % 20.68 %
2nd Quarter June - 6.89 % -2.12 % 22.07 %
1st Quarter March -14.72 % -4.65 % -12.58 % 23.75 %
FY (Year on Year)   - 22.99 % 20.76 % -


Back to ATRS Growth rate Comparisons >> Back to ATRS Growth rate Comparisons >>


Revenue first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #150
Healthcare Sector #518
Overall #3450

Revenue Y/Y Growth Statistics
High Average Low
127.93 % 30.74 % -34.03 %
(Dec 31 2014)   (Dec 31 2013)
Revenue first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #150
Healthcare Sector #518
Overall #3450
Revenue Y/Y Growth Statistics
High Average Low
127.93 % 30.74 % -34.03 %
(Dec 31 2014)   (Dec 31 2013)

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Antares Pharma Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
72.74 % 7.16 % -34.87 %
(Jun 30 2015)  


ATRS's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2022 Antares Pharma Inc disclosed drop in Revenue from the fourth quarter by -14.72% to $ 41.56 millions, from $ 48.73 millions achived in the previous reporting period.

But that's not important problem, as Antares Pharma Inc 's Revenue generally seem to plunge in this quarter.

Within Medical Equipment & Supplies industry 122 other companies have achieved higher Revenue quarter on quarter growth. While Antares Pharma Inc 's Revenue growth quarter on quarter, overall rank is 3161.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #123
Healthcare Sector #472
Overall #3161
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #123
Healthcare Sector #472
Overall #3161
Revenue Q/Q Growth Statistics
High Average Low
72.74 % 7.16 % -34.87 %
(Jun 30 2015)  


ATRS's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2022 Antares Pharma Inc disclosed drop in Revenue from the fourth quarter by -14.72% to $ 41.56 millions, from $ 48.73 millions achived in the previous reporting period.

But that's not important problem, as Antares Pharma Inc 's Revenue generally seem to plunge in this quarter.

Within Medical Equipment & Supplies industry 122 other companies have achieved higher Revenue quarter on quarter growth. While Antares Pharma Inc 's Revenue growth quarter on quarter, overall rank is 3161.


Antares Pharma Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2022)		 12 Months Ending
(Dec 31 2021)		 12 Months Ending
(Sep 30 2021)		 12 Months Ending
(Jun 30 2021)		 12 Months Ending
(Mar 31 2021)
Cumulative Revenue 12 Months Ending $ 183.46 $ 183.98 $ 179.39 $ 171.20 $ 158.60
Y / Y Revenue Growth (TTM) 15.67 % 22.98 % 25.18 % 24.41 % 18.66 %
Year on Year Revenue Growth Overall Ranking # 1486 # 1538 # 1167 # 1005 # 474
Seqeuential Revenue Change (TTM) -0.29 % 2.56 % 4.78 % 7.94 % 6.02 %
Seq. Revenue Growth (TTM) Overall Ranking # 2646 # 2307 # 1654 # 1505 # 2509


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Mar 31 2022 period, Antares Pharma Inc 's cumulative twelve months Revenue were $ 183 millions, company would post below average annual Revenue growth of 6.02% year on year, if the fiscal year would end at Mar 31 2022.
A slow-down in the Antares Pharma Inc 's Revenue growth from the 48.73% growth in Dec 31 2021.

In the Healthcare sector 228 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1486, from total ranking in previous quarter at 1538.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 122
Healthcare Sector # 229
Overall # 1486

Revenue TTM Y/Y Growth Statistics
High Average Low
94.9 %
 34.89 %
-10.81 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 122
Sector # 369
S&P 500 # 2646
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Mar 31 2022 period, Antares Pharma Inc 's cumulative twelve months Revenue were $ 183 millions, company would post below average annual Revenue growth of -10.81% year on year, if the fiscal year would end at Mar 31 2022.
A slow-down in the Antares Pharma Inc 's Revenue growth from the 48.73% growth in Dec 31 2021.

In the Healthcare sector 228 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1486, from total ranking in previous quarter at 1538.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 122
Healthcare Sector # 229
Overall # 1486

Revenue TTM Y/Y Growth Statistics
High Average Low
94.9 %
34.89 %
-10.81 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 122
Sector # 369
S&P 500 # 2646




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ATRS's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Mar 31 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2022
Sage Therapeutics Inc -0.06%$ -0.063 millions
Davita Inc -0.09%$ -0.087 millions
Axogen inc -0.10%$ -0.097 millions
Musclepharm Corporation-0.15%$ -0.152 millions
3m Company-0.25%$ -0.249 millions
Oncternal Therapeutics Inc -0.27%$ -0.267 millions
Glaukos Corp-0.42%$ -0.422 millions
Collegium Pharmaceutical Inc -0.70%$ -0.699 millions
Tenet Healthcare Corp-0.75%$ -0.753 millions
Nevro Corp -0.87%$ -0.867 millions
Antares Pharma Inc -1.25%$ -1.250 millions
Assure Holdings Corp -1.34%$ -1.343 millions
Elanco Animal Health Incorporated-1.37%$ -1.369 millions
Longeveron Inc -1.60%$ -1.596 millions
Rockwell Medical inc -1.67%$ -1.674 millions
Nanostring Technologies Inc -1.70%$ -1.698 millions
Mimedx Group Inc -1.79%$ -1.789 millions
Exagen Inc -1.82%$ -1.823 millions
Cryoport inc -1.84%$ -1.843 millions
Royalty Pharma Plc-1.92%$ -1.916 millions
Veru Inc -2.34%$ -2.339 millions
Femasys Inc -2.55%$ -2.545 millions
Delcath Systems Inc -2.58%$ -2.577 millions
Imagenebio Inc -2.59%$ -2.591 millions
Therapeuticsmd Inc -2.68%$ -2.683 millions
Ngm Biopharmaceuticals Inc -2.91%$ -2.906 millions
Livanova Plc-3.00%$ -3.000 millions
Lifevantage Corp-3.04%$ -3.037 millions
Reata Pharmaceuticals Inc -3.18%$ -3.178 millions
Becton Dickinson And Company-3.20%$ -3.200 millions


About Antares Pharma Inc Revenue Growth Rates (ATRS), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Antares Pharma Inc (CIK 1016169).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001016169-22-000044
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Antares Pharma Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.